Hysteroscopy combined dilatation and curettage, serum CA125 and CA19-9 play an important role in preserving fertility or endocrine function for early-stage endometrial cancer patients

Objective: The aim of the study was to evaluate the role of hysteroscopy combined dilatation and curettage (D&C), serum CA125 and CA19-9 in endometrial cancer (EC) patients who desire to preserve fertility or endocrine function. Materials and Methods: This retrospective study included a total of 622 patients with EC between January 2006 and December 2014. The consistency of preoperative and postoperative histopathological findings were compared in patients who underwent D&C with or without hysteroscopy. The incidence of positive peritoneal cytology was also compared to assess the safety of hysteroscopy. Receiver operating characteristic (ROC) curve was used to evaluate the role of preoperative serum CA125 and CA19-9 in predicting extrauterine metastasis. Results: In 151 patients who underwent hysteroscopy combined D&C, the consistency of pre- and postoperative pathology was higher than the remaining 447 patients who underwent classical D&C alone (83.44% vs. 74.94%, p < 0.05) and there was no significant difference in the incidence of positive peritoneal cytology between the two groups (2.64% vs. 2.73%, p > 0.05). ROC curve analysis results showed the CA125 serum level of 31.75 U/ml and CA19-9 serum level of 35.40 U/ml were the best cutoff to predict extrauterine metastasis in endometrial cancer, with 66.7% sensitivity, 83% specificity, and 61.9% sensitivity and 84.9% of specificity, respectively. Conclusions: Hysteroscopy combined D&C should be recommended for early-stage EC patients who desire to preserve fertility or endocrine function, and the preoperative serum levels of CA125 and CA19-9 were powerful in predicting tumor stage in these patients.

Endometrial carcinoma; Hysteroscopy; CA125; CA19-9.

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2015”. CA. Cancer. J. Clin., 2015, 65, 5.

[2] Ota T., Yoshida M., Kimura M., Kinoshita K.: “Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger”. Int. J. Gynecol. Cancer, 2005, 15, 657.

[3] Soliman P.T., Oh J.C., Schmeler K.M., Sun C.C., Slomovitz B.M., Gershenson D.M., et al.: “Risk factors for young premenopausal women with endometrial cancer”. Obstet. Gynecol., 2005, 105, 575.

[4] Loiacono R.M., Trojano G., Del Gaudio N., Kardhashi A., Deliso M.A., Falco G., et al.: “Hysteroscopy as a valid tool for endometrial pathology in patients with postmenopausal bleeding or asymptomatic patients with a thickened endometrium: hysteroscopic and histological results”. Gynecol. Obstet. Invest., 2015, 79, 210.

[5] Lee D.O., Jung M.H., Kim H.Y.: “Prospective comparison of biopsy results from curettage and hysteroscopy in postmenopausal uterine bleeding”. J. Obstet. Gynaecol. Res., 2011, 37, 1423.

[6] Huang G.S., Chiu L.G., Gebb J.S., Gunter M.J., Sukumvanich P., Goldbert G.L., et al.: “Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma”. Gynecol. Oncol., 2007, 107, 513.

[7] Chung H.H., Kim J.W., Park N.H., Song Y.S., Kang S.B., Lee, H.P.: “Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer”. Acta Obstet. Gynecol. Scand., 2006, 85, 1501.

[8] Han S.S., Lee S.H., Kim D.H., Kim J.W., Park N.H., Kang S.B., et al.: “Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer”. Acta Obstet. Gynecol. Scand., 2010, 89, 168.

[9] Baser E., Gungor T., Togrul C., Turkoglu O., Celen S.: “Preoperative prediction of poor prognostic parameters and adjuvant treatment in women with pure endometrioid type endometrial cancer: what is the significance of tumor markers?” Eur. J. Gynaecol. Oncol., 2014, 35, 513.

[10] Cherchi P.L., Dessole S., Ruiu G.A., Ambrosini G., Farina M., Capobianco G., et al.: “The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma”. Eur. J. Gynaecol. Oncol., 1999, 20, 315.

[11] Kim Y.B., Holschneider C.H., Ghosh K., Nieberg R.K., Montz F.J.: “Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature”. Cancer, 1997, 79, 320.

[12] Kaku T., Yoshikawa H., Tsuda H., Sakamoto A., Fukunaga M., Kuwabara Y., et al.: “Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome”. Cancer Lett., 2001, 167, 39.

[13] Win A.K., Reece J.C., Ryan S.: “Family history and risk of endometrial cancer: a systematic review and meta-analysis”. Obstet. Gynecol., 2015, 125, 89.

[14] Gruber S.B., Thompson W.D.: “A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group”. Cancer. Epidemiol. Biomarkers. Prev., 1996, 5, 411.

[15] Randall T.C., Kurman R.J.: “Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40”. Obstet. Gynecol., 1997, 90, 434.

[16] Penner K.R., Dorigo O., Aoyama C., Ostrzega N., Balzer B.L., Rao J., et al.: “Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy”. Gynecol. Oncol., 2012, 124, 542.

[17] Simpson A.N., Feigenberg T., Clarke B.A., Gien L.T., Ismiil N., Laframboise S., et al.: “Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin”. Gynecol. Oncol., 2014, 133, 229.

[18] Ben-Yehuda O.M., Kim Y.B., Leuchter R.S.: “Does hysteroscopy improve upon the sensitivity of dilatation and curettage in the diagnosis of endometrial hyperplasia or carcinoma?” Gynecol. Oncol., 1998, 68, 4.

[19] Gimpelson R.J., Rappold H.O.: “A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. A review of 276 cases”. Am. J. Obstet. Gynecol., 1988, 158, 3.

[20] Li X., Yang X., Yang Y., Ye H., Ye M.: “Value of hysteroscopy and dilatation and curettage in diagnosis of endometrial cancer”. Zhonghua Fu Chan Ke Za Zhi, 2015, 50, 120.

[21] Gu M., Shi W., Huang J., Barakat R.R., Thaler H.T., Saigo P.E.: “Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma”. Cancer, 2000, 90, 143.

[22] Kudela M., Pilka R.: “Is there a real risk in patients with endometrial carcinoma undergoing diagnostic hysteroscopy (HSC)?” Eur. J. Gynaecol. Oncol., 2001, 22, 342.

[23] Selvaggi L., Cormio G., Ceci O., Loverro G., Cazzolla A., Bettocchi S.: “Hysteroscopy does not increase the risk of microscopic extrauterine spread in endometrial carcinoma”. Int. J. Gynecol. Cancer, 2003, 13, 223.

[24] Niloff J.M., Klug T.L., Schaetzl E., Zurawski V.R. Jr., Knapp R.C., Bast R.C. Jr.: “Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix”. Am. J. Obstet. Gynecol., 1984, 148, 1057.

[25] Kim H.S., Park C.Y., Lee J.M., Lee J.K., Cho C.H., Kim S.M., et al.: “Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study”. Gynecol. Oncol., 2010, 118, 283.

[26] Jiang T., Huang L., Zhang S.: “Preoperative serum CA125: a useful marker for surgical management of endometrial cancer”. BMC Cancer, 2015, 15, 396.

[27] Hsieh C.H., ChangChien C.C., Lin H., Huang E.Y., Huang C.C., Lan K.C., et al.: “Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer?” Gynecol. Oncol., 2002, 86, 28.

[28] Alonso S., Castellanos T., Lapuente F., Chiva L.: “Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature”. Ecancermedicalscience, 2015, 9, 50